Hepion Pharmaceuticals director buys 200K shares

Hepion Pharmaceuticals, Inc. director Danina Fisher reported purchasing 200,000 common shares at $0.05 per share and 200,000 warrants reported at $0.00 per warrant on September 29, 2026.

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. director Danina Fisher reported purchasing 200,000 common shares at $0.05 per share and 200,000 warrants reported at $0.00 per warrant on September 29, 2026. After the transactions, she held 200,000 common shares and 200,000 warrants. The warrants have an exercise price of $0.06 per share and expire September 29, 2031. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Buyer: 400,000 shares

Net Buy 2 txns

Insider Fisher Danina

Role Director

Bought 400,000 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Warrants	200,000	$0.00	$0.00
Purchase	Common Stock	200,000	$0.05	$10K

Holdings After Transaction: Warrants — 200,000 contracts (Direct); Common Stock — 200,000 shares (Direct)

Key Figures

Common shares purchased: 200,000 shares Common share purchase price: $0.05 per share Warrants purchased: 200,000 warrants +4 more

7 metrics

Common shares purchased 200,000 shares September 29, 2026

Common share purchase price $0.05 per share September 29, 2026

Warrants purchased 200,000 warrants September 29, 2026

Reported warrant purchase price $0.00 per warrant September 29, 2026

Warrant exercise price $0.06 per share Warrants expire September 29, 2031

Common shares held after transactions 200,000 shares Following the September 29, 2026 transactions

Warrants held after transactions 200,000 warrants Following the September 29, 2026 transactions

Key Terms

Warrants, exercise price, Rule 10b5-1 plan

3 terms

Warrants financial

"200,000 warrants reported at $0.00 per warrant"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

exercise price financial

"exercise price of $0.06 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Rule 10b5-1 plan regulatory

"No Rule 10b5-1 plan is reported"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did HEPA director Danina Fisher purchase, and at what prices?

On September 29, 2026, Danina Fisher purchased 200,000 common shares at $0.05 per share and 200,000 warrants reported at $0.00 per warrant. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:31 PM Accepted by SEC EDGAR 10/02/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fisher Danina

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK, NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/29/2026		P		200,000	A	$0.05	200,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$0.06	09/29/2026		P		200,000		09/29/2026	09/29/2031	Commmon Stock	200,000	$0	200,000	D

Explanation of Responses:

	/s/ Danina Fisher	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)